Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 20/20 | 0.60 |
| ▸ | CHUK | O15111 | 5/20 | 0.60 |
| ▸ | AURKA | O14965 | 1/20 | 0.60 |
| ▸ | FLT3 | P36888 | 1/20 | 0.60 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.60 |
| ▸ | BTK | Q06187 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1686986 | 0.88 | IKBKB (0.60) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL3803112 | 0.84 | IKBKB (0.82) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL17101346 | 0.81 | IKBKB (0.53) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL3802568 | 0.81 | IKBKB (0.80) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL3796669 | 0.81 | IKBKB (0.67) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL3797086 | 0.81 | IKBKB (0.66) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL3796803 | 0.80 | IKBKB (0.80) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL1686790 | 0.79 | IKBKB (0.60) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL552458 | 0.79 | IKBKB (0.70) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL13020899 | 0.79 | IKBKB (0.68) | IKBKBCHUKAURKAFLT3CSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354539-B2 | Indole derivatives as IKK2 inhibitors | GLAXO GROUP LIMITED (GB) | 2013-01-15 | — | — | US | disclosed |
| US-8354539-B2 | Indole derivatives as IKK2 inhibitors | GLAXO GROUP LIMITED (GB) | 2013-01-15 | — | — | US | disclosed |
| US-20120010244-A1 | INDOLE DERIVATIVES AS IKK2 INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010244-A1 | INDOLE DERIVATIVES AS IKK2 INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010244-A1 | INDOLE DERIVATIVES AS IKK2 INHIBITORS | NFKBIA, IKBKG, IDO2 | IKBKB 5/4885CHUK 7/4885AURKA 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.